Immunology Section, Department of Medicine, University of Verona, 37134 Verona, Italy.
Cells. 2021 Oct 9;10(10):2700. doi: 10.3390/cells10102700.
Myeloid-derived suppressor cells (MDSCs) constitute a plastic and heterogeneous cell population among immune cells within the tumour microenvironment (TME) that support cancer progression and resistance to therapy. During tumour progression, cancer cells modify their metabolism to sustain an increased energy demand to cope with uncontrolled cell proliferation and differentiation. This metabolic reprogramming of cancer establishes competition for nutrients between tumour cells and leukocytes and most importantly, among tumour-infiltrating immune cells. Thus, MDSCs that have emerged as one of the most decisive immune regulators of TME exhibit an increase in glycolysis and fatty acid metabolism and also an upregulation of enzymes that catabolise essential metabolites. This complex metabolic network is not only crucial for MDSC survival and accumulation in the TME but also for enhancing immunosuppressive functions toward immune effectors. In this review, we discuss recent progress in the field of MDSC-associated metabolic pathways that could facilitate therapeutic targeting of these cells during cancer progression.
髓系来源的抑制细胞(MDSCs)是肿瘤微环境(TME)中免疫细胞中的一个具有可塑性和异质性的细胞群体,它们支持癌症的进展和对治疗的耐药性。在肿瘤进展过程中,癌细胞改变其代谢以维持增加的能量需求,以应对不受控制的细胞增殖和分化。这种癌细胞的代谢重编程在肿瘤细胞和白细胞之间建立了营养物质的竞争,最重要的是,在肿瘤浸润免疫细胞之间建立了竞争。因此,MDSCs 已成为 TME 中最具决定性的免疫调节剂之一,其表现为糖酵解和脂肪酸代谢增加,以及分解代谢必需代谢物的酶上调。这种复杂的代谢网络不仅对 MDSC 在 TME 中的存活和积累至关重要,而且对增强其对免疫效应物的免疫抑制功能也至关重要。在这篇综述中,我们讨论了 MDSC 相关代谢途径的最新进展,这些进展可能有助于在癌症进展过程中对这些细胞进行治疗性靶向。